Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm

Fred Hutchinson Cancer Center (FHCC)

Status: Withdrawn

Conditions: Pancreatic Neoplasm

Treatments: Other: Tumor Board Review; Other: Survey Administration; Procedure: Palliative Care Consultation; Other: Best Practice

Study type: Interventional

Funder types: Other

Identifiers

NCT06545344

RG1124214

NCI-2024-05662 (Registry Identifier)

20350 (Other Identifier)

Details and patient eligibility

About

This clinical trial evaluates a palliative care consultation for improving communication between providers and patients considering surgery for a pancreatic neoplasm. Pancreatic operations have known complications that can affect quality of life. Palliative care has been shown to improve patient reported quality of life and functional outcomes. Receiving a palliative care consultation may improve communication and decision making for patients considering surgery for a pancreatic neoplasm.

Full description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline.

ARM II: Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.

After completion of study intervention, patients are followed up 7 days after the tumor board visit and 90 days after initiation of treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults (18 years or older)
• Pancreatic neoplasm pathology
• Ability to read, write, and speak in English
• Has decisional capacity
• Expected to be seen and discussed at PCSC and seeing a surgeon as part of their tumor board evaluation

Exclusion criteria

• Metastatic pancreatic neoplasm
• Currently incarcerated
• Currently is or previously has received palliative care, or are unwilling to forego palliative care for the first 90 days post randomization
• Evidence of any behavior, condition, or circumstance (including, but not limited to: blindness, deafness, serious behavior or mental health conditions, discontinuing curative treatment, lack of access to technology, etc) that would interfere with their ability to complete study procedures as noted within the chart

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Arm I (Usual care)

Active Comparator group

Description:

Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline.

Treatment:

Other: Best Practice

Other: Survey Administration

Other: Tumor Board Review

Arm II (Palliative care visit)

Experimental group

Description:

Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.

Treatment:

Procedure: Palliative Care Consultation

Other: Survey Administration

Other: Tumor Board Review